Rusfertide (PTG-300)

FDA-approved product existsHepcidin Mimetic

Awaiting review, BioHarmony verdict

Not yet scored. Queued for review; until then rely on the status and sources below.

What is Rusfertide (PTG-300)?

FDA approved rusfertide as Mimrylo in August 2026 for the treatment of erythrocytosis in adults with polycythemia vera. It is a hepcidin mimetic given by subcutaneous injection, with dosing adjusted to keep hematocrit below 45%.

Saved on this device only.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelMIMRYLO prescribing information for erythrocytosis in adults with polycythemia vera

Label cadence: once weekly.

PopulationAdults with polycythemia vera and erythrocytosis
DoseStart at 19 mg once weekly. The label permits dose increases after at least 2 weeks at the current dose, following its titration table, to keep hematocrit below 45%. The recommended range is 9.5 mg to 108 mg once weekly. Doses above 54 mg require two injections. Doses greater than 82 mg should be administered on separate days.
RouteSubcutaneous injection in the abdomen or thigh, or the upper arm when given by a caregiver
FrequencyOnce weekly. Doses above 54 mg require two injections, and doses above 82 mg are given on separate days (day 1 and day 4 or 5).
DurationLong-term use within the approved indication, with complete blood counts every 2 to 4 weeks during dose modifications
PreparationLyophilized powder in 9.5 mg, 19 mg, 28 mg, 41 mg and 54 mg single-dose vials, co-packaged with a diluent prefilled syringe. Reconstitute with the provided diluent, swirl for about 2 minutes and do not shake. Use within 4 hours at 20 to 25 degrees C. Store at room temperature, do not freeze and protect from light.
Source: Dosage and Administration sections 2.1-2.4; Dosage Forms and Strengths section 3; How Supplied section 16

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingFDA-approved product exists; compounded copies are not FDA approved

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.